Health & Wellness

CG Oncology announced the publication of pivotal Phase 3 BOND-003 Cohort C study results in The Lancet Oncology, highlighting potential advances in cancer treatment.

• Deal Sucker Team
• July 28, 2026

Akari Therapeutics CEO discusses how increasing industry demand for advanced antibody-drug conjugate payloads positions the company for growth in oncology.

• Deal Sucker Team
• July 22, 2026

Fangzhou has launched Novo Nordisk’s once-weekly basal insulin and GLP-1 combination therapy in China, marking a significant step in diabetes treatment access.

• Deal Sucker Team
• July 20, 2026

4DMT announces promising two-year data from its PRISM Phase 2b clinical trial, showing potential benefits in wet AMD treatment. Details remain under review.

• Deal Sucker Team
• July 19, 2026

Lynk Pharmaceuticals announces the completion of patient enrollment in its Phase III trial for Zemprocitinib targeting ankylosing spondylitis, marking a key milestone.

• Deal Sucker Team
• July 15, 2026

Law firm Brayton Purcell LLP discusses a new medical report emphasizing the dangers of silicosis linked to artificial calcifications and control limitations.

• Deal Sucker Team
• July 14, 2026

TaiMed Biologics has received the TFDA drug license collection notice for Trogarz, moving closer to commercial launch in Taiwan.

• Deal Sucker Team
• July 8, 2026

The world’s first international patient begins treatment with a new CAR-T cell therapy for solid tumors at Jiahui International Cancer Center, marking a milestone in cancer care.

• Deal Sucker Team
• July 7, 2026

InnoCare has dosed the first patient in a clinical trial of its novel CDH17-targeted antibody-drug conjugate, ICP-B208, in China, marking a key development in cancer therapy research.

• Deal Sucker Team
• July 6, 2026

Ascletis has filed two Investigational New Drug applications with the U.S. FDA for obesity treatments, including a peptide injection and a co-formulation.

• Deal Sucker Team
• July 6, 2026